PMGC Holdings (ELAB) FY2025 10-K Risk Factors: 50 New, 28 Dropped

What the changes say

PMGC transitioned from a skincare firm into a diversified holding company acquiring manufacturing, packaging, and biotech businesses.
Operating cash burn significantly exceeds revenue, requiring heavy reliance on equity purchase facilities.
Assets and subsidiary equity are pledged as collateral to Streeterville Capital under financing agreements.
Frequent reverse stock splits reflect severe downward pressure on common stock and low liquidity.

What changed since the prior 10-K

New

NewRISKS RELATED TO OUR FINANCIAL CONDITION AND CAPITAL STRUCTURE
Our operating cash consumption significantly exceeds our revenue, and we may not be able to fund our operations without continued access to the capital markets
Operating cash consumption significantly exceeds revenue, requiring continuous external capital and debt or equity financing to fund operations.
NewRISKS RELATED TO OUR FINANCIAL CONDITION AND CAPITAL STRUCTURE
Our existing equity purchase facility may result in substantial dilution to our existing stockholders and may place downward pressure on the price of our Common Stock
Our equity purchase facility with Streeterville allows discounted share conversions, causing significant downward pressure and potential dilution for our Common Stock.
NewRISKS RELATED TO OUR FINANCIAL CONDITION AND CAPITAL STRUCTURE
Our equity interests in our key subsidiaries and the assets of those subsidiaries are pledged as collateral under our equity purchase facility with Streeterville, and a default on our obligations pursuant to such facility could result in the loss of our operating businesses
We pledged 100% of the equity and assets of subsidiaries AGA Precision Systems and Pacific Sun Packaging to Streeterville as collateral.
NewRISKS RELATED TO OUR FINANCIAL CONDITION AND CAPITAL STRUCTURE
We have conducted multiple reverse stock splits in a short period of time, which may adversely affect the market price of our Common Stock and investor confidence
Repeated reverse stock splits since November 2024 may diminish investor confidence and fail to maintain Nasdaq minimum bid price compliance.
NewRISKS RELATED TO OUR FINANCIAL CONDITION AND CAPITAL STRUCTURE
We may be unable to realize the expected value from the divestiture of our Elevai Skincare business, including earn-out payments
We may not realize earn-out payments or full value from the divestiture of our Elevai Skincare business if the buyer underperforms.
NewRISKS RELATED TO OUR FINANCIAL CONDITION AND CAPITAL STRUCTURE
Changes in tax laws or regulations could adversely affect our business and financial results
Changes in tax laws or disagreements with tax authorities regarding income and deduction allocations could increase our tax liabilities.
NewRISKS RELATED TO OUR HOLDING COMPANY STRUCTURE AND ACQUISITION STRATEGY
Our diversified holding company structure may make our business more complex and difficult to manage
Our diversified holding company structure across biotechnology, manufacturing, and packaging strains our small management team and complicates internal controls.
NewRISKS RELATED TO OUR HOLDING COMPANY STRUCTURE AND ACQUISITION STRATEGY
Our results depend on our ability to allocate capital effectively across our subsidiaries and investments
Misallocation of capital across our subsidiaries and PMGC Capital investments could result in opportunity costs and impairment charges.
NewRISKS RELATED TO OUR HOLDING COMPANY STRUCTURE AND ACQUISITION STRATEGY
We may not realize anticipated benefits from operating as a platform of multiple businesses
We may fail to achieve operational synergies across multiple businesses, while corporate overhead and compliance costs outweigh potential benefits.
NewRISKS RELATED TO OUR HOLDING COMPANY STRUCTURE AND ACQUISITION STRATEGY
Our growth strategy depends on acquisitions, which involve significant risks and uncertainties
Our acquisition growth strategy involves risks including integration difficulties, unknown liabilities, goodwill impairments, and dilution from issuing stock.
NewRISKS RELATED TO OUR HOLDING COMPANY STRUCTURE AND ACQUISITION STRATEGY
The purchase price allocations for our acquisitions may be preliminary and subject to adjustment, which could materially affect our reported financial results
Preliminary purchase price allocations for acquisitions are subject to adjustments that could affect our consolidated balance sheet.
NewRISKS RELATED TO OUR HOLDING COMPANY STRUCTURE AND ACQUISITION STRATEGY
We have recorded goodwill on our consolidated balance sheet that may be subject to impairment, which could adversely affect our financial results
A decline in expected future cash flows or stock price could trigger non-cash goodwill impairment charges for our acquisitions.
NewRISKS RELATED TO OUR HOLDING COMPANY STRUCTURE AND ACQUISITION STRATEGY
Earn-out and contingent consideration arrangements may result in disputes or financial obligations that adversely affect our results
NewRISKS RELATED TO OUR HOLDING COMPANY STRUCTURE AND ACQUISITION STRATEGY
We depend on the founders and key employees of our acquired businesses, and their departure could adversely affect the performance of those businesses
NewRisks Related to Northstrive Biosciences Inc. (Biotechnology)
Our biotechnology subsidiary, Northstrive Biosciences, is at an early stage of product development, and we may not develop products that can be successfully commercialized
NewRisks Related to Northstrive Biosciences Inc. (Biotechnology)
If we are unable to successfully complete preclinical testing and clinical trials of the Licensed Products or experience significant delays in doing so, our business will be materially harmed
NewRisks Related to Northstrive Biosciences Inc. (Biotechnology)
Since we rely on third parties to conduct, supervise and monitor pre-clinical and clinical trials, their failure to perform satisfactorily may materially harm our business
NewRisks Related to Northstrive Biosciences Inc. (Biotechnology)
Our therapeutic products may be expensive to manufacture, and they may not be profitable if we are unable to control the costs to manufacture them
NewRisks Related to Pacific Sun Packaging, Inc. (Specialty Packaging)
The packaging industry is highly competitive and includes large multinational packaging companies as well as smaller specialized providers
NewRisks Related to Pacific Sun Packaging, Inc. (Specialty Packaging)
Pacific Sun Packaging’s revenue depends on the IT hardware industry, which is subject to cyclical and secular changes
NewRisks Related to Pacific Sun Packaging, Inc. (Specialty Packaging)
Pacific Sun Packaging is dependent on a limited number of suppliers for raw materials and components
NewRisks Related to AGA Precision Systems LLC (Precision Manufacturing)
AGA Precision Systems operates in industries subject to stringent regulatory requirements, including International Traffic in Arms Regulations
NewRisks Related to AGA Precision Systems LLC (Precision Manufacturing)
Maintaining and renewing industry certifications, including AS9100, is critical to AGA’s ability to serve its customers
NewRisks Related to AGA Precision Systems LLC (Precision Manufacturing)
AGA Precision Systems has incurred, and may continue to incur, significant repair and maintenance costs, and the condition of its equipment may require ongoing capital investment
NewRisks Related to AGA Precision Systems LLC (Precision Manufacturing)
AGA Precision Systems has historically operated without a formal sales and marketing function, which may limit its growth
NewRisks Related to All Operating Subsidiaries
Our operations across multiple industries expose us to diverse and potentially conflicting market risks
NewRisks Related to All Operating Subsidiaries
We may be subject to liability for workplace safety and employment-related claims across our operating subsidiaries
NewRisks Related to All Operating Subsidiaries
Our insurance coverage may be inadequate to protect us against all potential losses and liabilities
NewRisks Related to All Operating Subsidiaries
A portion of our revenue may be derived from a limited number of customers
NewRisks Related to All Operating Subsidiaries
Disruptions in supply chains or manufacturing operations could adversely affect our business
NewRISKS RELATED TO OUR INVESTMENT ACTIVITIES (PMGC CAPITAL)
PMGC Capital LLC may be deemed an “investment company” under the Investment Company Act of 1940, which could impose significant regulatory burdens
NewRISKS RELATED TO OUR INVESTMENT ACTIVITIES (PMGC CAPITAL)
PMGC Capital’s investment activities subject us to market risk, and we may incur losses on our investment portfolio
NewRISKS RELATED TO REGULATORY, LEGAL AND INTELLECTUAL PROPERTY MATTERS
We may become subject to litigation, regulatory proceedings, or governmental investigations that could be costly and time-consuming
NewRISKS RELATED TO REGULATORY, LEGAL AND INTELLECTUAL PROPERTY MATTERS
We are subject to anti-corruption, anti-bribery, and similar laws, and non-compliance could expose us to significant penalties
NewRISKS RELATED TO REGULATORY, LEGAL AND INTELLECTUAL PROPERTY MATTERS
Changes in U.S. trade policy, tariffs, and international relations could adversely affect our supply chain and cost structure
NewRISKS RELATED TO REGULATORY, LEGAL AND INTELLECTUAL PROPERTY MATTERS
Patents held by other persons may result in infringement claims against us that are costly to defend and which may limit our ability to use disputed technologies
NewRISKS RELATED TO REGULATORY, LEGAL AND INTELLECTUAL PROPERTY MATTERS
A recall or suspension of sale of our products, or the discovery of serious safety issues, could have a significant negative impact on us
NewRISKS RELATED TO REGULATORY, LEGAL AND INTELLECTUAL PROPERTY MATTERS
Regulations governing our products could harm our business
NewRISKS RELATED TO REGULATORY, LEGAL AND INTELLECTUAL PROPERTY MATTERS
We may incur product liability claims that could harm our business, and past product liability claims relating to our previously divested Elevai Skincare products could still adversely affect our business
NewRISKS RELATED TO REGULATORY, LEGAL AND INTELLECTUAL PROPERTY MATTERS
We may not have sufficient product liability insurance, which may leave us vulnerable to future claims we will be unable to satisfy
NewRISKS RELATED TO OUR MANAGEMENT AND GOVERNANCE
Our corporate governance documents and Nevada law may have anti-takeover effects that could discourage, delay, or prevent a change in control
NewRISKS RELATED TO OUR MANAGEMENT AND GOVERNANCE
Graydon Bensler serves as both our Chief Executive Officer and Chief Financial Officer, which presents governance risks and limitations
NewRISKS RELATED TO OUR MANAGEMENT AND GOVERNANCE
Significant related-party transactions with entities controlled by our executive officers and directors may present conflicts of interest
NewRISKS RELATED TO OUR MANAGEMENT AND GOVERNANCE
We have previously identified a material weakness in our internal control over financial reporting, and there can be no assurance that additional material weaknesses will not be identified in the future
NewRISKS RELATED TO OUR DEPENDENCE ON THIRD PARTIES
Certain market opportunity data and forecasts in this Annual Report were obtained from third-party sources and were not independently verified by us
NewRISKS RELATED TO THE OWNERSHIP OF OUR SECURITIES
We have a significant number of shares of Series B Preferred Stock outstanding with voting rights that may dilute the voting power of Common Stock holders
NewRISKS RELATED TO THE OWNERSHIP OF OUR SECURITIES
Our Common Stock may be subject to significant volatility due to limited public float and market conditions
NewRISKS RELATED TO THE OWNERSHIP OF OUR SECURITIES
We may not be able to continue to satisfy listing requirements of Nasdaq to maintain a listing of our Common Stock
NewRISKS RELATED TO THE OWNERSHIP OF OUR SECURITIES
Changes to Nasdaq listing requirements, including potential minimum market capitalization requirements, could adversely affect our continued listing
NewRISKS RELATED TO THE OWNERSHIP OF OUR SECURITIES
Future issuances of our Common Stock or securities convertible into or exercisable for our Common Stock could cause the market price of our Common Stock to decline and result in additional dilution to our stockholders

Dropped

DroppedRisks Related to Our Financial Condition
Our current growth may not be indicative of our future growth and, if we begin to grow rapidly, we may not be able to effectively manage our growth or evaluate our future prospects. If we fail to effectively manage our future growth or evaluate our future prospects, our business could be adversely affected
DroppedRisks Related to Our Business, Our Portfolio Companies, and the Biotechnology Industry
If we are unable to secure strategic commercial partnerships, licensing agreements, funding, or other key business relationships following successful clinical results, our revenue potential may be limited
DroppedRisks Related to Our Business, Our Portfolio Companies, and the Biotechnology Industry
If we fail to cost-effectively acquire, license, or develop biotechnology assets, our business could be adversely affected
Minimal historical growth and small employee headcount of two full-time and one part-time employee.
DroppedRisks Related to Our Business, Our Portfolio Companies, and the Biotechnology Industry
If we fail to secure strategic partnerships or commercialization agreements, our revenue potential may be limited
DroppedRisks Related to Our Business, Our Portfolio Companies, and the Biotechnology Industry
Our brand and reputation may be diminished due to intellectual property disputes, perceived scientific failures, or negative publicity, which could have an adverse effect on our business
DroppedRisks Related to Our Business, Our Portfolio Companies, and the Biotechnology Industry
Economic downturns, shifts in healthcare investment trends, regulatory changes, and evolving market demand for biotechnology products could negatively affect our business
DroppedRisks Related to Our Business, Our Portfolio Companies, and the Biotechnology Industry
Our business is at an early stage of asset development, and we may not successfully develop, License, or commercialize biotechnology assets
Reliance on strategic commercial partnerships rather than an internal sales force for biotechnology assets.
DroppedRisks Related to Our Business, Our Portfolio Companies, and the Biotechnology Industry
Uncertainty in market demand, regulatory approval, and investment cycles could impact our future growth
DroppedRisks Related to Our Business, Our Portfolio Companies, and the Biotechnology Industry
We may incur product liability or intellectual property claims that could harm our business
Risks associated with cost-effectively acquiring, licensing, and developing biotechnology assets.
DroppedRisks Related to Our Business, Our Portfolio Companies, and the Biotechnology Industry
There is a risk that our insurance policies and our portfolio companies’ insurance policies are inadequate to cover liabilities
Dependence on pharmaceutical partnerships to commercialize biotechnology assets and generate revenue.
DroppedRisks Related to Our Business, Our Portfolio Companies, and the Biotechnology Industry
We face additional business risks through our multi-strategy investment vehicle, PMGC Capital LLC, which risks may adversely impact our financial performance
Brand and reputation risks from intellectual property disputes or perceived scientific failures.
DroppedRisks Related to Our Business, Our Portfolio Companies, and the Biotechnology Industry
Our portfolio companies’ products and technologies may fail to achieve the broad adoption necessary for commercial success, which may negatively impact our financial performance
Sensitivity of the biotechnology sector to economic downturns, healthcare investment trends, and regulatory changes.
DroppedRisks Related to Our Business, Our Portfolio Companies, and the Biotechnology Industry
The outcome of clinical and product testing for our portfolio companies is uncertain
DroppedRisks Related to Our Business, Our Portfolio Companies, and the Biotechnology Industry
Even if our portfolio companies’ technologies are successful, rapid advancements in biotechnology could make them obsolete
DroppedRisks Related to Our Business, Our Portfolio Companies, and the Biotechnology Industry
Biotechnology products often require complex, costly manufacturing processes. If our portfolio companies fail to optimize production, scale efficiently, or negotiate favorable supply chain agreements, their profit margins may be significantly lower than competing therapies
DroppedRisks Related to Our Business, Our Portfolio Companies, and the Biotechnology Industry
Evolving regulations governing biotechnology, pharmaceuticals, and investments could negatively impact our business
DroppedRisks Related to Our Business, Our Portfolio Companies, and the Biotechnology Industry
We expect to invest material efforts and financial resources in the development of the Licensed Products. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of the Licensed Products
DroppedRisks Related to Our Business, Our Portfolio Companies, and the Biotechnology Industry
International trade disputes, including U.S. trade tariffs and retaliatory tariffs, could adversely impact our business
Early stage of asset development without commercialized biotechnology assets at scale.
DroppedRisks Related to Our Business, Our Portfolio Companies, and the Biotechnology Industry
Significant political, trade, regulatory developments, and other circumstances beyond our control, could have a material adverse effect on our financial condition or results of operations
Uncertainty in market demand, regulatory approvals (FDA, EMA), and investment cycles.
DroppedRisks Related to Our Business, Our Portfolio Companies, and the Biotechnology Industry
Regulatory changes or actions may alter the nature of an investment in us or restrict the use of cryptocurrencies in a manner that adversely affects our business, prospects, or operations
Product liability or intellectual property claims related to drug development and medical devices.
DroppedRisks Related to Our Business, Our Portfolio Companies, and the Biotechnology Industry
Our business, operations, financial position and clinical development plans and timelines, could be materially adversely affected by the continuing military action in Ukraine and the war between Israel and Hamas
Inadequate general liability and D&O insurance policies for portfolio companies.
DroppedRisks Related to Our Dependence on Third Parties
Although we have not experienced any security breaches or attempted security breaches and continue to invest in security measures, we cannot be certain that our defensive measures, and those employed by our third-party vendors, will be sufficient to defend against all such current and future methods
Investment losses and market volatility risks through multi-strategy investment vehicle PMGC Capital LLC.
DroppedRisks Related to Our Intellectual Property
We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors
DroppedRisks Related to the Ownership of Our Securities
The price of our Common Stock may be adversely affected by the future issuance and sale of shares of our Common Stock or other equity securities
Failure of portfolio companies' products to achieve broad adoption by physicians and healthcare institutions.
DroppedRisks Related to the Ownership of Our Securities
Future sales by stockholders, or the perception that such sales may occur, may depress the price of our Common Stock
DroppedRisks Related to the Ownership of Our Securities
The issuance of shares upon exercise of derivative securities may cause immediate and substantial dilution to our existing stockholders
DroppedRisks Related to the Ownership of Our Securities
Our Common Stock is currently listed on Nasdaq and we must meet certain financial and liquidity criteria to maintain such listing. If we violate the maintenance requirements for continued listing of our Common Stock, our Common Stock may be delisted
DroppedRisks Related to the Ownership of Our Securities
New laws, regulations and standards relating to corporate governance and public disclosure may create uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming

Reworded

100% rewrittenRisks Related to Northstrive Biosciences Inc. (Biotechnology)
Our products under development could be rendered obsolete by technological or other medical advances
Updated from general biotechnology obsolescence to specifically cite GLP-1 drugs for obesity and muscle wasting research rendering products uneconomical.
Was: Our acquired technologies and products under development could be rendered obsolete by technological, regulatory, or medical advances
100% rewrittenRISKS RELATED TO OUR HOLDING COMPANY STRUCTURE AND ACQUISITION STRATEGY
Potential business combinations could require significant management attention, prove difficult to integrate, and adversely affect our operating results
Streamlined risk language regarding business combination integration difficulties, loss of customers, and unexpected liabilities.
Was: Potential business combinations and licensing agreements could require significant management attention and prove difficult to integrate, which could divert attention away from management, disrupt our normal course of business, dilute stockholder value, and adversely affect our operating results
99% rewrittenRisks Related to All Operating Subsidiaries
A disruption in our operations could have an adverse effect on our business
Shifted focus from biotech R&D and clinical trials to traditional manufacturing and distribution operational hazards like industrial accidents and labor strikes.
99% rewrittenRISKS RELATED TO REGULATORY, LEGAL AND INTELLECTUAL PROPERTY MATTERS
Government regulations relating to marketing and advertising may restrict, inhibit or delay our ability to sell our products
Condensed FDA and FTC marketing and advertising compliance warnings regarding product claims and unapproved indications.
Was: Government regulations and private party actions relating to the marketing and advertising of biotechnology and pharmaceutical products may restrict, inhibit, or delay commercialization efforts
99% rewrittenRISKS RELATED TO REGULATORY, LEGAL AND INTELLECTUAL PROPERTY MATTERS
Our employees, independent contractors, consultants, distributors, vendors and strategic partners may engage in misconduct or improper activities
Broadened third-party misconduct risks from biotech partners and CROs to include distributors, vendors, and consultants across all subsidiaries.
Was: Our employees, independent contractors, consultants, strategic partners, and third parties may engage in unethical misconduct, regulatory noncompliance, or other improper activities that could harm our business
99% rewrittenRISKS RELATED TO OUR MANAGEMENT AND GOVERNANCE
We have a limited operating history at our current scale and with our current business model, which may make it difficult to evaluate our business and future prospects
Updated operating history to reflect the January 2025 divestiture of skincare and mid-2025 acquisition of operating subsidiaries as a diversified holding company.
Was: We have a limited operating history at our current scale, which may make it difficult to evaluate our business and future prospects
98% rewrittenRISKS RELATED TO OUR MANAGEMENT AND GOVERNANCE
We may be unable to accurately forecast revenue and appropriately plan our expenses
Added that historical growth rates of recently acquired businesses may not predict future performance under PMGC ownership.
Was: We may be unable to accurately forecast revenue and appropriately plan our expenses in the future
97% rewrittenRISKS RELATED TO OUR MANAGEMENT AND GOVERNANCE
If we cannot maintain our Company culture or focus on our mission as we grow, our success and competitive position may be harmed
Changed culture preservation focus from scientific integrity and biotech innovation to managing corporate culture across multi-industry public company acquisitions.
Was: If we cannot maintain our company culture or focus on our strategic mission as we grow, our success and competitive position may be harmed
97% rewrittenRISKS RELATED TO OUR MANAGEMENT AND GOVERNANCE
If we lose key personnel or are unable to attract and retain qualified personnel, we may be unable to execute our business plan
Was: If we lose key personnel or are unable to attract and retain other qualified personnel, we may be unable to execute our business plan, and our business could be materially adversely affected
95% rewrittenRISKS RELATED TO OUR DEPENDENCE ON THIRD PARTIES
Our reliance on non-employee consultants, third-party vendors, and operational contractors may lead to delays in development of our proposed products and operation of our businesses
Was: Our reliance on the activities of our non-employee consultants, third-party vendors, and operational contractors, whose activities are not wholly within our control, may lead to delays in development of our proposed products
91% rewrittenRISKS RELATED TO REGULATORY, LEGAL AND INTELLECTUAL PROPERTY MATTERS
The divestiture of our Elevai Skincare business could negatively impact our operations and strategic positioning
91% rewrittenRISKS RELATED TO OUR DEPENDENCE ON THIRD PARTIES
We or our third-party vendors may experience network or system failures, cybersecurity attacks, or other technology risks
Was: We or our third-party vendors may experience in the future network or system failures, or service interruptions, including cybersecurity attacks, or other technology risks. Our inability to protect our systems and data against such risks could harm our business and reputation
91% rewrittenRISKS RELATED TO OUR DEPENDENCE ON THIRD PARTIES
Our business may be negatively impacted by cybersecurity threats and other security threats and disruptions
Was: Our business could be negatively impacted by cybersecurity threats and other security threats and disruptions
89% rewrittenRisks Related to Northstrive Biosciences Inc. (Biotechnology)
We license from a third party the rights to our therapeutic product candidates and are therefore subject to the risk that we lose this license after investing substantial resources
Was: We license from a third party the rights to product candidates related to the potential prevention and treatment of muscular and obesity-related conditions, and are therefore subject to the risk that we lose the license after investing substantial resources into the research and development of these product candidates
86% rewrittenRISKS RELATED TO OUR MANAGEMENT AND GOVERNANCE
The requirements of being a public company may strain our resources, divert management’s attention and affect our results of operations
85% rewrittenRISKS RELATED TO REGULATORY, LEGAL AND INTELLECTUAL PROPERTY MATTERS
If our third-party suppliers, logistics providers, and manufacturers do not comply with ethical business practices or applicable laws, our reputation and business could be harmed
Was: If our third-party suppliers, logistics, and manufacturers do not comply with ethical business practices or with applicable laws and regulations, our reputation, business, financial condition, results of operations and prospects could be harmed
84% rewrittenRISKS RELATED TO REGULATORY, LEGAL AND INTELLECTUAL PROPERTY MATTERS
If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed
81% rewrittenRisks Related to All Operating Subsidiaries
To sustain our growth, we will need to increase the size of our organization, and we may encounter difficulties managing growth across multiple subsidiaries
Was: To sustain our continued growth, we will need to increase the size of our organization, and we may encounter difficulties managing our growth, which could adversely affect our results of operations
74% rewrittenRISKS RELATED TO REGULATORY, LEGAL AND INTELLECTUAL PROPERTY MATTERS
If we, or our third-party manufacturers fail to comply with environmental laws and regulations, we could become subject to fines or penalties
Was: If we, or our third-party manufacturers fail to comply with environmental laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
73% rewrittenRisks Related to Northstrive Biosciences Inc. (Biotechnology)
The Licensed Products may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance
65% rewrittenRISKS RELATED TO REGULATORY, LEGAL AND INTELLECTUAL PROPERTY MATTERS
We may not be able to protect our proprietary technology, which may harm our ability to operate profitably
Was: We may not be able to protect our proprietary technology, which could harm our ability to operate profitably
60% rewrittenRisks Related to Northstrive Biosciences Inc. (Biotechnology)
Because our future commercial success with respect to our Licensed Products (as defined below) depends on gaining regulatory approval, we cannot generate therapeutic revenue without obtaining such approvals
Was: Because our future commercial success with respect to the Licensed Products depends on gaining regulatory approval for our products, we cannot generate revenue without obtaining approvals
58% rewrittenRISKS RELATED TO OUR DEPENDENCE ON THIRD PARTIES
We depend on our collaborators to help us develop and test our proposed products, and our ability to develop and commercialize products may be impaired or delayed if collaborations are unsuccessful
57% rewrittenRISKS RELATED TO OUR FINANCIAL CONDITION AND CAPITAL STRUCTURE
We will need additional capital to conduct our operations and develop our products and businesses, and our ability to obtain the necessary funding is uncertain
Was: We will need additional capital to conduct our operations and develop our products and our ability to obtain the necessary funding is uncertain
50% rewrittenRISKS RELATED TO OUR FINANCIAL CONDITION AND CAPITAL STRUCTURE
If we fail to generate sufficient cash flow from our operations, we will be unable to continue to develop and commercialize our products and grow our businesses
Was: If we fail to generate sufficient cash flow from our operations, we will be unable to continue to develop and commercialize our products
50% rewrittenRISKS RELATED TO THE OWNERSHIP OF OUR SECURITIES
We may be subject to securities litigation, which is expensive and could divert our management’s attention
48% rewrittenRISKS RELATED TO THE OWNERSHIP OF OUR SECURITIES
If there is no active public market for our Common Stock, you may be unable to sell your shares at or above your purchase price
47% rewrittenRISKS RELATED TO THE OWNERSHIP OF OUR SECURITIES
Our Common Stock may be affected by limited trading volume and price fluctuations, which could adversely impact the value of our Common Stock
39% rewrittenRISKS RELATED TO REGULATORY, LEGAL AND INTELLECTUAL PROPERTY MATTERS
We may need to license additional intellectual property from third parties in the future, and such licenses may not be available on commercially reasonable terms
Was: We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms
38% rewrittenRISKS RELATED TO OUR FINANCIAL CONDITION AND CAPITAL STRUCTURE
Our financial statements have been prepared on a going-concern basis and our continued operations are in doubt
35% rewrittenRISKS RELATED TO THE OWNERSHIP OF OUR SECURITIES
If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
28% rewrittenRISKS RELATED TO REGULATORY, LEGAL AND INTELLECTUAL PROPERTY MATTERS
Certain of our technology may not be subject to protection through patents, which leaves us vulnerable to theft of our technology
21% rewrittenRisks Related to Northstrive Biosciences Inc. (Biotechnology)
Because third parties may be developing competitive products without our knowledge, we may later learn that competitive products are superior to the Licensed Products
Was: Because third parties may be developing competitive products without our knowledge, we may later learn that competitive products are superior to the Licensed Products which may force us to terminate our research efforts of one or more product candidates

All 90 risk factors

Headings as the filing states them, in filing order.

RISKS RELATED TO OUR FINANCIAL CONDITION AND CAPITAL STRUCTURE

01Our financial statements have been prepared on a going-concern basis and our continued operations are in doubt38% rewritten
02We have a history of net losses, and we may not be able to achieve or maintain profitability in the future
03Our operating cash consumption significantly exceeds our revenue, and we may not be able to fund our operations without continued access to the capital marketsNew
04We will need additional capital to conduct our operations and develop our products and businesses, and our ability to obtain the necessary funding is uncertain57% rewritten
05Our existing equity purchase facility may result in substantial dilution to our existing stockholders and may place downward pressure on the price of our Common StockNew
06Our equity interests in our key subsidiaries and the assets of those subsidiaries are pledged as collateral under our equity purchase facility with Streeterville, and a default on our obligations pursuant to such facility could result in the loss of our operating businessesNew
07We have conducted multiple reverse stock splits in a short period of time, which may adversely affect the market price of our Common Stock and investor confidenceNew
08If we fail to generate sufficient cash flow from our operations, we will be unable to continue to develop and commercialize our products and grow our businesses50% rewritten
09We may need, but be unable, to obtain additional funding on satisfactory terms, which could dilute our stockholders or impose burdensome financial restrictions on our business
10We may be unable to realize the expected value from the divestiture of our Elevai Skincare business, including earn-out paymentsNew
11Changes in tax laws or regulations could adversely affect our business and financial resultsNew

RISKS RELATED TO OUR HOLDING COMPANY STRUCTURE AND ACQUISITION STRATEGY

12Our diversified holding company structure may make our business more complex and difficult to manageNew
13Our results depend on our ability to allocate capital effectively across our subsidiaries and investmentsNew
14We may not realize anticipated benefits from operating as a platform of multiple businessesNew
15Our growth strategy depends on acquisitions, which involve significant risks and uncertaintiesNew
16Potential business combinations could require significant management attention, prove difficult to integrate, and adversely affect our operating results100% rewritten
17The purchase price allocations for our acquisitions may be preliminary and subject to adjustment, which could materially affect our reported financial resultsNew
18We have recorded goodwill on our consolidated balance sheet that may be subject to impairment, which could adversely affect our financial resultsNew
19Earn-out and contingent consideration arrangements may result in disputes or financial obligations that adversely affect our resultsNew
20We depend on the founders and key employees of our acquired businesses, and their departure could adversely affect the performance of those businessesNew

Risks Related to Northstrive Biosciences Inc. (Biotechnology)

21Our biotechnology subsidiary, Northstrive Biosciences, is at an early stage of product development, and we may not develop products that can be successfully commercializedNew
22Because our future commercial success with respect to our Licensed Products (as defined below) depends on gaining regulatory approval, we cannot generate therapeutic revenue without obtaining such approvals60% rewritten
23The development and acquisition of therapeutic product candidates could expose us to significant legal and regulatory risks
24If we are unable to successfully complete preclinical testing and clinical trials of the Licensed Products or experience significant delays in doing so, our business will be materially harmedNew
25The Licensed Products may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance73% rewritten
26We license from a third party the rights to our therapeutic product candidates and are therefore subject to the risk that we lose this license after investing substantial resources89% rewritten
27Our products under development could be rendered obsolete by technological or other medical advances100% rewritten
28Since we rely on third parties to conduct, supervise and monitor pre-clinical and clinical trials, their failure to perform satisfactorily may materially harm our businessNew
29Because third parties may be developing competitive products without our knowledge, we may later learn that competitive products are superior to the Licensed Products21% rewritten
30Our therapeutic products may be expensive to manufacture, and they may not be profitable if we are unable to control the costs to manufacture themNew

Risks Related to Pacific Sun Packaging, Inc. (Specialty Packaging)

31The packaging industry is highly competitive and includes large multinational packaging companies as well as smaller specialized providersNew
32Pacific Sun Packaging’s revenue depends on the IT hardware industry, which is subject to cyclical and secular changesNew
33Pacific Sun Packaging is dependent on a limited number of suppliers for raw materials and componentsNew

Risks Related to AGA Precision Systems LLC (Precision Manufacturing)

34AGA Precision Systems operates in industries subject to stringent regulatory requirements, including International Traffic in Arms RegulationsNew
35Maintaining and renewing industry certifications, including AS9100, is critical to AGA’s ability to serve its customersNew
36AGA Precision Systems has incurred, and may continue to incur, significant repair and maintenance costs, and the condition of its equipment may require ongoing capital investmentNew
37AGA Precision Systems has historically operated without a formal sales and marketing function, which may limit its growthNew

Risks Related to All Operating Subsidiaries

38Our operations across multiple industries expose us to diverse and potentially conflicting market risksNew
39We may be subject to liability for workplace safety and employment-related claims across our operating subsidiariesNew
40Our insurance coverage may be inadequate to protect us against all potential losses and liabilitiesNew
41A portion of our revenue may be derived from a limited number of customersNew
42Disruptions in supply chains or manufacturing operations could adversely affect our businessNew
43A disruption in our operations could have an adverse effect on our business99% rewritten
44To sustain our growth, we will need to increase the size of our organization, and we may encounter difficulties managing growth across multiple subsidiaries81% rewritten

RISKS RELATED TO OUR INVESTMENT ACTIVITIES (PMGC CAPITAL)

45PMGC Capital LLC may be deemed an “investment company” under the Investment Company Act of 1940, which could impose significant regulatory burdensNew
46PMGC Capital’s investment activities subject us to market risk, and we may incur losses on our investment portfolioNew

RISKS RELATED TO REGULATORY, LEGAL AND INTELLECTUAL PROPERTY MATTERS

47We may become subject to litigation, regulatory proceedings, or governmental investigations that could be costly and time-consumingNew
48We are subject to anti-corruption, anti-bribery, and similar laws, and non-compliance could expose us to significant penaltiesNew
49Changes in U.S. trade policy, tariffs, and international relations could adversely affect our supply chain and cost structureNew
50If we fail to protect or enforce our intellectual property, others could compete against us more directly and we may not be able to compete effectively in our market
51Certain of our technology may not be subject to protection through patents, which leaves us vulnerable to theft of our technology28% rewritten
52We may not be able to protect our proprietary technology, which may harm our ability to operate profitably65% rewritten
53Patents held by other persons may result in infringement claims against us that are costly to defend and which may limit our ability to use disputed technologiesNew
54If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our target markets
55If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed84% rewritten
56We may need to license additional intellectual property from third parties in the future, and such licenses may not be available on commercially reasonable terms39% rewritten
57A recall or suspension of sale of our products, or the discovery of serious safety issues, could have a significant negative impact on usNew
58Regulations governing our products could harm our businessNew
59Government regulations relating to marketing and advertising may restrict, inhibit or delay our ability to sell our products99% rewritten
60We may incur product liability claims that could harm our business, and past product liability claims relating to our previously divested Elevai Skincare products could still adversely affect our businessNew
61We may not have sufficient product liability insurance, which may leave us vulnerable to future claims we will be unable to satisfyNew
62Our employees, independent contractors, consultants, distributors, vendors and strategic partners may engage in misconduct or improper activities99% rewritten
63If we, or our third-party manufacturers fail to comply with environmental laws and regulations, we could become subject to fines or penalties74% rewritten
64If our third-party suppliers, logistics providers, and manufacturers do not comply with ethical business practices or applicable laws, our reputation and business could be harmed85% rewritten
65The divestiture of our Elevai Skincare business could negatively impact our operations and strategic positioning91% rewritten

RISKS RELATED TO OUR MANAGEMENT AND GOVERNANCE

66Our corporate governance documents and Nevada law may have anti-takeover effects that could discourage, delay, or prevent a change in controlNew
67If we lose key personnel or are unable to attract and retain qualified personnel, we may be unable to execute our business plan97% rewritten
68Graydon Bensler serves as both our Chief Executive Officer and Chief Financial Officer, which presents governance risks and limitationsNew
69Significant related-party transactions with entities controlled by our executive officers and directors may present conflicts of interestNew
70We may be unable to accurately forecast revenue and appropriately plan our expenses98% rewritten
71We have a limited operating history at our current scale and with our current business model, which may make it difficult to evaluate our business and future prospects99% rewritten
72We have previously identified a material weakness in our internal control over financial reporting, and there can be no assurance that additional material weaknesses will not be identified in the futureNew
73The requirements of being a public company may strain our resources, divert management’s attention and affect our results of operations86% rewritten
74If we cannot maintain our Company culture or focus on our mission as we grow, our success and competitive position may be harmed97% rewritten

RISKS RELATED TO OUR DEPENDENCE ON THIRD PARTIES

75We depend on our collaborators to help us develop and test our proposed products, and our ability to develop and commercialize products may be impaired or delayed if collaborations are unsuccessful58% rewritten
76Our reliance on non-employee consultants, third-party vendors, and operational contractors may lead to delays in development of our proposed products and operation of our businesses95% rewritten
77Certain market opportunity data and forecasts in this Annual Report were obtained from third-party sources and were not independently verified by usNew
78We or our third-party vendors may experience network or system failures, cybersecurity attacks, or other technology risks91% rewritten
79Our business may be negatively impacted by cybersecurity threats and other security threats and disruptions91% rewritten

RISKS RELATED TO THE OWNERSHIP OF OUR SECURITIES

80Our Common Stock may be affected by limited trading volume and price fluctuations, which could adversely impact the value of our Common Stock47% rewritten
81We have a significant number of shares of Series B Preferred Stock outstanding with voting rights that may dilute the voting power of Common Stock holdersNew
82Our Common Stock may be subject to significant volatility due to limited public float and market conditionsNew
83We may not be able to continue to satisfy listing requirements of Nasdaq to maintain a listing of our Common StockNew
84Changes to Nasdaq listing requirements, including potential minimum market capitalization requirements, could adversely affect our continued listingNew
85We currently do not intend to declare dividends on our Common Stock in the foreseeable future and, as a result, your returns on your investment may depend solely on the appreciation of our common stock
86An investment in our securities is speculative and there can be no assurance of any return on any such investment
87If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline35% rewritten
88If there is no active public market for our Common Stock, you may be unable to sell your shares at or above your purchase price48% rewritten
89We may be subject to securities litigation, which is expensive and could divert our management’s attention50% rewritten
90Future issuances of our Common Stock or securities convertible into or exercisable for our Common Stock could cause the market price of our Common Stock to decline and result in additional dilution to our stockholdersNew

Other PMGC Holdings 10-Ks

FY2024 10-K risk factors
68 risks
PMGC Holdings faces significant going-concern doubts after incurring net losses of $6,245,737 in 2024. The company transitioned from skincare to a biotechnology holding model, relying heavily on third-party licensing like the MOA Life Plus agreement for lead asset EL-22. Operations are constrained by having only two full-time employees and one part-time employee.
Filed Mar 28, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.